News - Avectas in the Media
July 4th, 2019 - Maynooth, Ireland: Avectas CEO, Dr Michael Maguire will attend 'Global Ireland Summit' on July 8th 2019 on invitation of An Taoiseach Leo Varadkar & An Tánasite Simon Coveney. The event will bring together Key Partners from Government Department & Agencies, the Irish Business Community, Civic Society, Arts, Culture, Youth Representatives and Heads of Mission of resident diplomatic missions in Ireland.
Avectas look forward to attending this event and representing the Irish Business Community.
April 15th, 2019 - Maynooth, Ireland: Avectas will attend ASGCT 2019 (American Society of Gene & Cell Therapy), The 22nd Annual Meeting will take place April 29th - May 2nd in Washington D.C., USA (Washington Hilton Hotel). Avectas will present a poster during the conference on the following topic:
Poster Title: Efficient Gene Editing of Primary Human T Cells using Solupore Ex Vivo Cell Engineering Platform
April 9th, 2019 – Ireland – Cell engineering technology business Avectas has completed a US$10 million equity financing with a group of experienced biotechnology investors. The investment round was led by leading pharmaceutical sector investor Seamus Mulligan. Avectas collaborates with leading cell and gene therapy businesses and academic institutions to address their cell engineering challenges using its patented Solupore® technology.
“The Avectas team is delighted to receive this significant endorsement from a highly experienced group of investors,” said Dr. Michael Maguire, co-founder and CEO of Avectas. “This funding, which builds on our recent Horizon 2020 award, provides us with the financial resources to accelerate the development, scale-up and commercialisation of Solupore®.”
Cell and gene therapies offer the potential to transform the treatment of diseases, including cancer, for millions of patients worldwide. However new engineering technologies are required to enable these cutting-edge therapies to achieve their potential. Avectas is developing a patented, non-viral, cell engineering technology which efficiently engineers therapeutic cells, at scale, while maintaining optimal cell functionality.
Avectas to Present at 2019 Cell & Gene Meeting on the Mediterranean
Maynooth, Ireland March 11, 2019 – Avectas announced today that Dr. Michael Maguire, CEO will present at the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain.
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mediterranean will bring together the entire cell and gene therapy community from Europe and beyond. Covering a wide range of commercialization topics from market access and regulatory issues to manufacturing and financing the sector, the program will feature expert-led panels, extensive one-on-one partnering capabilities, and exclusive networking opportunities.
The meeting will feature presentations by 50+ leading public and private companies, highlighting technical and clinical achievements over the past 12 months in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies, as well as 35+ panelists and featured speakers.
The following are specific details regarding Avectas’s presentation at the conference:
Event: 2019 Cell & Gene Meeting on the Mediterranean
Date: Tuesday 23rd April 2019
Location: Gaudi 2, Hotel Arts Barcelona, Marina 19-21, 08005 Barcelona, Spain
A live video webcast of all company presentations will be available at: http://www.meetingonthemed.com/webcast and will also be published on the conference website shortly after the event.
Please visit www.meetingonthemed.com for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. Investors should contact Chelsey Hathaway at email@example.com and interested media should contact Lyndsey Scull at firstname.lastname@example.org.
Avectas shortlisted in the ‘US- Ireland Research Innovation Awards’
Maynooth, Ireland - Avectas have been shortlisted in the An Irish microenterprise or SME with US corporate links Category of the US-Ireland Research Innovation Awards, the US partner we selected was Mintz Levin (US Patent Attorneys). The awards are run in conjunction with American Chamber of Commerce and Royal Irish Academy with support from KPMG, Ulster Bank and Irish Times. The shortlisted organisations were announced at the American Chamber of Commerce Transatlantic Conference in Croke Park on March 7th 2019.
Further details about the shortlisted organisations are listed here.
The winners in each of the categories of the awards will be announced at the American Chamber of Commerce annual dinner on Friday, 17 May in the Clayton Hotel, Burlington Road, Dublin.
Avectas named ‘Bio Science Lab of the Year’ at The Irish Laboratory Awards 2019
Maynooth, Ireland - Avectas named ‘Bio Science Lab of the Year’ at The Irish Laboratory Awards 2019. The winners were revealed at the black-tie gala awards ceremony on Thursday, March 7th, at the Ballsbridge Hotel, Dublin.
Congratulations to the Avectas Team, this is fantastic recognition for each and every member. The judging panel commended Avectas for being the only Irish company to be awarded Horizon 2020 Funding in in their call in 2018.
Avectas to Present at Biotech Showcase 2019
Maynooth, Ireland – Avectas, has announced that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square.
Dr. Michael Maguire, CEO will present at Biotech Showcase™ as follows:
Date: Monday, January 7th, 2019
Time: 11.45am (PST)
Room: Franciscan C (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
“We are delighted that Avectas will be presenting at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. We are thrilled to, once again, be hosting what we believe will be the great strategic networking opportunity of 2019.”
ABOUT BIOTECH SHOWCASE
Biotech Showcase™ is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its eleventh year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high quality programs that support the biotechnology and broader life sciences industry.
Follow Biotech Showcase on Twitter at @EBDGroup and @Demy_Colton and tag your posts with #BiotechShowcase.
Avectas Scientific Advisory Board
Avectas SAB Meeting was held in London, UK on November 16th 2018. The Senior Avectas Management Team was joined by Scientific Advisory Board Chair, Prof. Mark Lowdell, in hosting the following newly appointed members;
- Prof. Bruce L. Levine
- Dr. Evren Alici
- Dr. Karl Peggs
Avectas look forward working closely with the Scientific Advisory Board to further develop the Avectas Technology, Solupore®. Further details about the board members appointments and experience can be found here.
Maynooth team secures €2.1m EU funding for cancer therapy
Avectas, an Irish company developing cutting-edge technology to help cure cancers, has secured €2.1 million funding under the European Union’s Horizon 2020 programme. The Maynooth-based biotech is the only Irish company to be awarded funding in the current round of Horizon 2020 – the EU Framework Programme for Research and Innovation. Avectas is developing a technology that temporarily makes permeable cells extracted from a patient and allows them to be re-engineered to attack cancers before being infused back into patients. Its approach addresses two key challenges in the immunotherapy approach to tackling the disease – the reliance on viruses to help re-engineer cells and the length of the costly cell engineering process. Under current immunotherapy approaches, pharma companies can wait for years for the required virus to become available. The subsequent cell engineering process can take up to 22 days. The Avectas permubalisation approach does away with the need for viruses and reduces the time involved in the cell engineering process.
Read more: The Irish Times March 20th 2018
Read more: The Irish Times April 5th 2018
Avectas to Present at Biotech Showcase 2018
Dublin, 02/01/2017 – Avectas, a biotechnology company, developing a novel vector-free cell engineering technology today announced it will present a corporate overview at Biotech Showcase 2018, during the course of one of the industry's largest annual healthcare investor meetings, J.P. Morgan Annual Healthcare Conference, in San Francisco on January 8th.
Dr. Michael Maguire, CEO will present at the Biotech Showcase™ as follows:
Date: Monday, January 8th, 2018
Time: 2.00 pm (PST)
Room: Franciscan - C (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
Our ambition is to be the market leading vector-free delivery technology for next-generation cell and gene therapies. Avectas is a biotechnology company developing Solupore®, a novel vector-free cell engineering technology addressing challenges in intracellular delivery and manufacturing in the immuno-oncology space including CAR-T and gene editing.
About the Biotech Showcase™:
The Biotech Showcase™ produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to private and public biotechnology and life sciences companies during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that Avectas will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”
Director of Business Development
More information: www.avectas.com
Additional links and information:
Follow Avectas on Twitter: @Avectas
Follow Biotech Showcase on Twitter: @EBDGroup and @Demy_Colton - #BiotechShowcase